Junya Junya Peng

Dr. Junya Junya Peng


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2018 in Breast Cancer: Basic and Clinical Research
Verified
Journal Article
Open access
JPJunya Junya Peng
Junya Junya Peng
WWWenqian Wang
Wenqian Wang
SHSurong Hua
Surong Hua
LLLulu Liu
Lulu Liu
Cells can secrete extracellular vesicles (EVs) to communicate with neighboring or distant cells by EVs which are composed of a lipid bilayer containing transmembrane proteins and enclosing cytosolic proteins, lipids, and nucleic acids. Breast Cancer is the most frequently diagnosed malignancy with more than 1 million new cases each year and ranks the leading cause of cancer mortality in women worldwide. In this review, we will discuss recent progresses of the roles and mechanisms of cancer-derived EVs in metastatic breast cancer, with a special attention on tumor microenvironment construction, progression, and chemo/radiotherapy responses. This review also covers EV roles as biomarker and therapeutic target in clinical application.

3 April 2024 in American Journal of Surgical Pathology
Verified
Journal Article
Open access
YLYuanhao Liu
Yuanhao Liu
JTJiajuan Tu
Jiajuan Tu
YSYihong Bs Shi
Yihong Bs Shi
JPJunyi Bs Pang
Junyi Bs Pang
QHQi Huang
Qi Huang
WWWenming WU
Wenming WU
The diagnosis of solid pseudopapillary neoplasm of the pancreas (SPN) can be challenging due to potential confusion with other pancreatic neoplasms, particularly pancreatic neuroendocrine tumors (NETs), using current pathological diagnostic markers. We conducted a comprehensive analysis of bulk RNA sequencing data from SPNs, NETs, and normal pancreas, followed by experimental validation. This analysis revealed an increased accumulation of peroxisomes in SPNs. Moreover, we observed significant upregulation of the peroxisome marker ABCD1 in both primary and metastatic SPN samples compared with normal pancreas and NETs. To further investigate the potential utility of ABCD1 as a diagnostic marker for SPN via immunohistochemistry staining, we conducted verification in a large-scale patient cohort with pancreatic tumors, including 127 SPN (111 primary, 16 metastatic samples), 108 NET (98 nonfunctional pancreatic neuroendocrine tumor, NF-NET, and 10 functional pancreatic neuroendocrine tumor, F-NET), 9 acinar cell carcinoma (ACC), 3 pancreatoblastoma (PB), 54 pancreatic ductal adenocarcinoma (PDAC), 20 pancreatic serous cystadenoma (SCA), 19 pancreatic mucinous cystadenoma (MCA), 12 pancreatic ductal intraepithelial neoplasia (PanIN) and 5 intraductal papillary mucinous neoplasm (IPMN) samples. Our results indicate that ABCD1 holds promise as an easily applicable diagnostic marker with exceptional efficacy (AUC=0.999, sensitivity=99.10%, specificity=100%) for differentiating SPN from NET and other pancreatic neoplasms through immunohistochemical staining.

1 May 2025 in The Journal of Pathology: Clinical Research
Verified
Journal Article
Open access
YLYuanhao Liu
Yuanhao Liu
JPJunya Junya Peng
Junya Junya Peng
YZYupei Zhao
Yupei Zhao
WWWenze Wang
Wenze Wang
Solid pseudopapillary neoplasm (SPN) of the pancreas is a rare, low‐grade malignant tumor, representing 0.9–2.7% of all exocrine pancreatic tumors. SPN patients generally have a favorable prognosis with a 5‐year survival rate exceeding 95% following complete surgical resection. Accurate diagnosis is crucial to avoid unnecessary treatments. Currently, SPN diagnosis relies on imaging techniques such as CT and MRI, along with immunohistochemical analysis of biopsy and resection samples. The main challenge in diagnosis is the potential inability to accurately identify recurrent or metastatic SPN, as well as ‘malignant’ SPN, due to the lack of specific biomarkers. Advances in high‐throughput omics technologies, including genomics, transcriptomics, proteomics and metabolomics, have opened new avenues for identifying novel biomarkers for SPN. Additional, liquid biopsy techniques have enabled more comprehensive analysis of biosamples such as pancreatic cyst fluid, offering promising prospects for preoperative diagnosis. This review highlights recent research on SPN diagnosis, focusing on immunohistochemical markers, tissue sampling methods and the potential of omics approaches. It also discusses the challenges and opportunities in improving diagnostic accuracy, particularly for high‐grade and metastatic SPNs.

8 April 2024 in Science Bulletin
Verified
Journal Article
Closed access
JLJie Li
Jie Li
JCJiahui Chen
Jiahui Chen
XSXin Sun
Xin Sun
HYHeli Yang
Heli Yang
KSKeyong Sun
Keyong Sun
XLXun Lan
Xun Lan

30 April 2026 in Cancer Cell
Verified
Journal Article
Closed access
MZMeilian Zhuo
Meilian Zhuo
YLYong Li
Yong Li
YZYifeng Zhang
Yifeng Zhang
CYChenlu Yang
Chenlu Yang
DZDi Zou
Di Zou
CDCharles J. David
Charles J. David

1 April 2026 in Chinese Clinical Oncology
Verified
Journal Article
Open access
PDF file
JPJunya Junya Peng
Junya Junya Peng
XPXu Pan
Xu Pan
Background: Early hepatocellular carcinoma (HCC) remains difficult to diagnose because of its insidious and asymptomatic onset. Liquid biopsy provides a promising non-invasive approach for early tumor detection. 5-Hydroxymethylcytosine (5-hmC), the oxidation product of 5-methylcytosine (5-mC), has emerged as an informative epigenetic mark reflecting tumor-associated alterations during hepatocarcinogenesis. Methods: Using an XGBoost-based ensemble learning framework, we identified cfDNA 5-hmC markers that defined an early HCC 5-hmC signature (eHMS). The signature was assessed in training and validation cohorts using receiver operating characteristic (ROC) analysis, with the area under the curve (AUC) as the primary performance metric. Results: We defined a 19-gene cfDNA 5-hmC signature (eHMS), which showed high diagnostic accuracy for early HCC across multiple precancerous states, with AUCs of 92.3% (healthy controls vs. early HCC), 82.5% [benign liver lesions (BLL) vs. early HCC], 78.8% [chronic hepatitis B (CHB) vs. early HCC], 81.3% (liver cirrhosis vs. early HCC), and 89.4% when pooling all non-HCC, further validated in an external cfDNA cohort (AUC =93.5%). When traced to tissue 5-mC, the 5-mC-related eHMS (MeHMS) score distinguished tumors from adjacent tissues with an AUC of 99.9% and showed improved discriminatory performance compared with alpha-fetoprotein (AFP, AUC =71.5%). Moreover, the signature may reflect early metabolic reprogramming and provide prognostic value by stratifying patients for survival and disease progression. Conclusions: Our findings indicate that the eHMS represents a promising biomarker for liquid biopsy in early HCC surveillance.